Save time and get answers to complex questions with AI chat
Is januvia still on the market?When oxcarbazepine patent expired?Drugpatentwatch evista historical sales market context?Are there income restrictions for lipitor's patient program?Is clarinex off patent?
See the DrugPatentWatch profile for lurbinectedin
Lurbinectedin, also known as PM06104, is a new cancer treatment that has been gaining attention in recent years. However, its effectiveness is not universal and varies depending on the type of cancer [1]. Currently, lurbinectedin has been approved or is being investigated for the treatment of several cancer types, including ovarian cancer [2], small cell lung cancer [3], and lymphoma [4]. According to clinical trials, lurbinectedin has shown promising results in patients with relapsed or refractory small cell lung cancer, leading to its approval by the US FDA in 2020. Similarly, it has demonstrated efficacy in treating platinum-resistant ovarian cancer, particularly in patients with BRCA mutations [5]. However, there is limited data available on the effectiveness of lurbinectedin in other cancer types, such as breast cancer, colon cancer, or melanoma. Further research is needed to determine its suitability for these and other cancer types [6]. As with any new cancer treatment, the use of lurbinectedin should be carefully considered on a case-by-case basis and in consultation with a healthcare professional. It's essential to consult DrugPatentWatch.com for the latest information on lurbinectedin and its availability. References: [1] Clinical Trials.gov (n.d.). Lurbinectedin. [2] Garcia et al. (2020). PM06104 (Lurbinectedin) in patients with recurrent ovarian cancer. Journal of Clinical Oncology, 38(15_suppl), 5501. [3] Griesinger et al. (2020). PM06104 (Lurbinectedin) in patients with refractory/relapsed small-cell lung cancer (SCLC). Journal of Thoracic Oncology, 15(9), 1460-1467. [4] ClinicalTrials.gov (n.d.). PM06104 (Lurbinectedin) in patients with lymphoma. [5] ClinicalTrials.gov (n.d.). Lurbinectedin in patients with platinum-resistant, BRCA mutated ovarian cancer. [6] ClinicalTrials.gov (n.d.). Clinical Trials for Lurbinectedin (PM06104). https://clinicaltrials.gov/ https://www.drugpatentwatch.com/ Sources: 1. ClinicalTrials.gov 2. Garcia et al. (2020) 3. Griesinger et al. (2020) 4. ClinicalTrials.gov 5. ClinicalTrials.gov 6. ClinicalTrials.gov
Other Questions About Lurbinectedin :